drugset
drugset / Trial / NCT03746327

Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal

NCT03746327 ↗

Phase 4 Completed 30 enrolled Fundacion Clinic per a la Recerca Biomédica
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections caused by tedizolid susceptible microorganisms treated with implant removal in one or two stages at 6 months of followup after stopping tedizolid treatment.

Timeline

Start
2020-02-13
Primary completion
2024-01-31
Completion
2024-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tedizolid Small molecule 200 mg Oral

Indications

periprosthetic joint infection